P106: Maintenance treatment with granulocyte/monocyte adsorption in patients with inflammatory bowel disease and an initial response to treatment: a Swedish long-term prospective registry studyECCO '16 Amsterdam
2016
P107: IL-34 and IL-36 family expressing cytotoxic T-cells and plasmacytoid dendritic cells are increased
in patients with active inflammatory bowel diseaseECCO '16 Amsterdam
2016
P108: Cytokine levels differ during pregnancy amongst women with ulcerative colitis and Crohn’s diseaseECCO '16 Amsterdam
2016
P109: Effect of dysbiosis on the growth and colitis susceptibility in DSS colitis modelECCO '16 Amsterdam
2016
P110: Cigarette smoke modulates the effect of dextran sulfate sodium–induced colitis on a subpopulation of T-cells in blood and colon in miceECCO '16 Amsterdam
2016
P111: Differences in therapies and intestinal resection rates between adult and elderly onset Crohn’s diseaseECCO '16 Amsterdam
2016
P113: Quality of life in paediatric Crohn’s disease: data from the Imagekids studyECCO '16 Amsterdam
2016
P114: Predictors of clinical response during adalimumab therapy in Crohn’s disease patients: a German non-interventional studyECCO '16 Amsterdam
2016
P117: Comparison between calprotectin and HMGB1 as faecal biomarkers of intestinal inflammation in paediatric and adult inflammatory bowel diseaseECCO '16 Amsterdam
2016
P120: Faecal calprotectin and S100A12 detect the early response to treatment by quantifying colonic inflammation in patients with ulcerative colitisECCO '16 Amsterdam
2016
P121: Patients’ point of view regarding acceptability and usefulness of inflammatory bowel diseases monitoring tools: results from a nationwide multicentre study (the ACCEPT study)ECCO '16 Amsterdam
2016
P122: Role of diffusion-weighted imaging in MRI-enterography for the evaluation of surgical risk in patients with Crohn’s diseaseECCO '16 Amsterdam
2016
P123: Significance of serological markers in the disease course of ulcerative colitisECCO '16 Amsterdam
2016